MOUNTAIN VIEW, Calif., Nov. 13 /PRNewswire/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today announced that Helen Kastrissios, Ph.D., senior associate scientist, Pharsight Strategic Consulting Services, will speak to members of the Australian pharmaceutical industry and medical researchers attending the third Australian Health and Medical Research Congress (AH&MRC), to be held at the Melbourne Convention Center, Melbourne, Australia, November 26-December 1, 2006.
Dr. Kastrissios will speak on the value of modeling and simulation in drug development, and will present a case study in which integrated pharmacokinetic-pharmacodynamic models were developed to bridge clinical study results between different regions and to anticipate the clinical efficacy and therapeutic dose range of a novel compound. Dr. Kastrissios will join other presenters from industry and academia in a symposium on model-based drug development sponsored by the Australasian Society of Clinical and Experimental Pharmacologists & Toxicologists, and will co-chair a related panel discussion. Additional information can be found at www.ahmrcongress.org.au/program.htm .
“Model-based drug development, as recognized by the FDA in its Critical Path Initiative, continues to show value for improving the quality of drug development decisions,” said Shawn O’Connor, Pharsight President, CEO and chairman. “Drug development can benefit from the quantitative application of drug-disease models to simulate expected clinical response of new compounds, and to support critical program strategy and study design decisions. Pharsight is pleased to participate in Melbourne at this distinguished gathering of drug development and medical professionals. We look forward to exchanging information and best practices on the strategic application of modeling and simulation to support drug development in Australia and across the Asia-Pacific region.”
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
Registered Trademarks and Trademarks
Pharsight(R) is a registered trademark of Pharsight Corporation.
Pharsight Corporation
CONTACT: investors, Douglas Sherk or Jennifer Beugelmans, +1-415-896-6820,or media, Jen Saunders, +1-646-277-8720, all of EVC Group, for PharsightCorporation
Web site: http://www.pharsight.com//
